| 1. |
|
|
| 2. |
|
|
| 3. |
- Bausch, A. R., et al.
(författare)
-
Influence of bacteria on shell dissolution in dead gastropod larvae and adult Limacina helicina pteropods under ocean acidification conditions
- 2018
-
Ingår i: Marine Biology. - : Springer Science and Business Media LLC. - 0025-3162 .- 1432-1793. ; 165:2
-
Tidskriftsartikel (refereegranskat)abstract
- Ocean acidification (OA) increases aragonite shell dissolution in calcifying marine organisms. It has been proposed that bacteria associated with molluscan shell surfaces in situ could damage the periostracum and reduce its protective function against shell dissolution. However, the influence of bacteria on shell dissolution under OA conditions is unknown. In this study, dissolution in dead shells from gastropod larvae and adult pteropods (Limacina helicina) was examined following a 5-day incubation under a range of aragonite saturation states (Omega(arag); values ranging from 0.5 to 1.8) both with and without antibiotics. Gastropod and pteropod specimens were collected from Puget Sound, Washington (48 degrees 33'19.N, 122 degrees 59'49''W and 47 degrees 41'11''N, 122 degrees 25'23''W, respectively), preserved, stored, and then treated in August 2015. Environmental scanning electron microscopy (ESEM) was used to determine the severity and extent of dissolution, which was scored as mild, severe, or summed (mild + severe) dissolution. Shell dissolution increased with decreasing Omega(arag). In gastropod larvae, there was a significant interaction between the effects of antibiotics and Omega(arag) on severe dissolution, indicating that microbes could mediate certain types of dissolution among shells under low Omega(arag). In L. helicina, there were no significant interactions between the effects of antibiotics and Omega(arag) on dissolution. These findings suggest that bacteria may differentially influence the response of some groups of shelled planktonic gastropods to OA conditions. This is the first assessment of the microbial-chemical coupling of dissolution in shells of either gastropod larvae or adult L. helicina under OA.
|
|
| 4. |
- Evers, AWM, et al.
(författare)
-
Implications of Placebo and Nocebo Effects for Clinical Practice: Expert Consensus
- 2018
-
Ingår i: Psychotherapy and psychosomatics. - : S. Karger AG. - 1423-0348 .- 0033-3190. ; 87:4, s. 204-210
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background:</i></b> Placebo and nocebo effects occur in clinical or laboratory medical contexts after administration of an inert treatment or as part of active treatments and are due to psychobiological mechanisms such as expectancies of the patient. Placebo and nocebo studies have evolved from predominantly methodological research into a far-reaching interdisciplinary field that is unravelling the neurobiological, behavioural and clinical underpinnings of these phenomena in a broad variety of medical conditions. As a consequence, there is an increasing demand from health professionals to develop expert recommendations about evidence-based and ethical use of placebo and nocebo effects for clinical practice. <b><i>Methods:</i></b> A survey and interdisciplinary expert meeting by invitation was organized as part of the 1st Society for Interdisciplinary Placebo Studies (SIPS) conference in 2017. Twenty-nine internationally recognized placebo researchers participated. <b><i>Results:</i></b> There was consensus that maximizing placebo effects and minimizing nocebo effects should lead to better treatment outcomes with fewer side effects. Experts particularly agreed on the importance of informing patients about placebo and nocebo effects and training health professionals in patient-clinician communication to maximize placebo and minimize nocebo effects. <b><i>Conclusions:</i></b> The current paper forms a first step towards developing evidence-based and ethical recommendations about the implications of placebo and nocebo research for medical practice, based on the current state of evidence and the consensus of experts. Future research might focus on how to implement these recommendations, including how to optimize conditions for educating patients about placebo and nocebo effects and providing training for the implementation in clinical practice.
|
|
| 5. |
|
|
